- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition ; volume:7 ; number:1 ; day:25 ; month:10 ; year:2019 ; pages:1-14 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (25.10.2019), 1-14, 12.2019
- Creator
-
Mao, Wendy
Ghasemzadeh, Ali
Freeman, Zachary T.
Obradovic, Aleksandar
Chaimowitz, Matthew G.
Nirschl, Thomas R.
McKiernan, Emily
Yegnasubramanian, Srinivasan
Drake, Charles G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0758-y
- URN
-
urn:nbn:de:101:1-2020021722384328155122
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mao, Wendy
- Ghasemzadeh, Ali
- Freeman, Zachary T.
- Obradovic, Aleksandar
- Chaimowitz, Matthew G.
- Nirschl, Thomas R.
- McKiernan, Emily
- Yegnasubramanian, Srinivasan
- Drake, Charles G.
- SpringerLink (Online service)
Other Objects (12)
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
Discovery of Benzo (d) imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
Selectively Binding a Bromodomain
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
Discovery of Benzo (d) imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
Selectively Binding a Bromodomain
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT
Dietary compound resveratrol is a pan-BET bromodomain inhibitor
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer
Discovery of Benzo (d) imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Impact of BET bromodomain inhibition on KRAS-mutated non-small cell lung cancer
Selectively Binding a Bromodomain
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia